Your SlideShare is downloading. ×
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Programa científico 26 Congreso ECNP Barcelona 2013
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Programa científico 26 Congreso ECNP Barcelona 2013

340

Published on

Programa científico dedicado al trastorrno bipolar del 26 th ECNP Congress 2013

Programa científico dedicado al trastorrno bipolar del 26 th ECNP Congress 2013

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
340
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.       Programa Científico con las actividades del 26 ECNP Congress dedicadas al trastorno bipolar C.08: Bipolar disorder: the evolving story Educational financial support provided by AstraZeneca Sunday 16:45 - 18:30 Room: Room J Chair Roger McIntyre, Canada Presentations C.08.01: Improving patient outcomes in bipolar disorder Eduard Vieta, Spain C.08.02: A disease for life? Beyond acute episodes in bipolar disorder Guy Goodwin, United Kingdom Session Type Satellite symposium
  • 2.   C.13: The multidimensional perspective of Bipolar I disorder Educational financial support provided by H. Lundbeck A/S Monday 16:45 - 18:30 Room: Room M2 Chair Andrea Fagiolini, Italy Presentations C.13.01: The manic depressive spectrum, the DSM5 perspective Andrea Fagiolini, Italy C.13.02: Bipolar mixed states, recognition and course Allan H. Young, United Kingdom C.13.03: Treatment of mixed states Michael Berk, Australia Session Type Satellite symposium CA.01: Bipolar treatment café Sunday 16:10 - 16:40 Room: Outside Auditorium Session Type Scientific Café                  
  • 3.   S.05: An update on the psychopharmacology of bipolar disorder Pharmacological treatment of bipolar disorder may change depending on the illness phase and needs to be specifically tailored for each patient. Moreover, due to the complexity and multidimensional nature of bipolar illness, a treatment regimen which ensures a sustained long-term response may require using a combination of many drugs. A variety of guidelines exist for bipolar disorders, covering both management of acute mood episodes and long-term prophylaxis; the majority of them include lithium in their recommendations for first-line maintenance therapy. Divalproex, lamotrigine and sometimes olanzapine are also included as other first-line maintenance therapies. Certainly, there have been many developments in the field of bipolar disorder, including new placebo-controlled trials assessing not only traditional maintenance therapies, but also newer options such as aripiprazole, long-acting risperidone, olanzapine, oxcarbazepine, quetiapine, ziprasidone, asenapine and cariprazine. The risk-benefit ratio associated with AD use in BD remains unclear. Hence, it is important to ascertain, as far as possible, how to best use these drugs through the evaluation of factors supposedly involved in the outcomes of AD treatment in BD. The rationale for holding this symposium stems from the need to translate the accumulated psychopharmacological evidence of bipolar disorders into a useful guide for clinical practice.
  • 4.   Sunday 14:30 - 16:10 Room: Auditorium Chairs Eduard Vieta, Spain Aysegül Yildiz, Turkey Presentations 14:30-14:55 S.05.01: Lithium: still a cornerstone in the long-term treatment of bipolar disorder? Willem A. Nolen, The Netherlands 14:55-15:20 S.05.02: New developments in the pharmacotherapy of bipolar disorders Joseph R. Calabrese, USA 15:20-15:45 S.05.03: Atypical antipsychotics in bipolar disorder and schizophrenia: similarities and discrepancies Stefan Leucht, Germany 15:45-16:10 S.05.04: The role of antidepressants in bipolar disorder Isabella Pacchiarotti, Spain Session Type Symposium Track Clinical Treatment track              
  • 5.     S.11: Epigenetics: challenging new findings in psychiatry Epigenetic regulation is known to be involved in several psychiatric disorders, especially in stress-related disorders, Alzheimer disease, and alcohol related diseases. Although epigenetics is a relatively new area of biological psychiatry, both animal model and human studies on the role of transcriptional programs in cell fate decisions in response to stress environment are becoming increasingly popular. Epigenetic differences have been found in post-mortem brains of people with a major depressive disorder. Recent studies also suggest that DNA methylation at certain neurotransmitter gene sites may be involved in alcohol dependence and there are now encouraging findings in Alzheimer research. This symposium will discuss the epigenetic regulation involved in stress-related disorders, Alzheimer disease, or Fetal Alcohol Syndrome. The symposium aims to foster advancements in behavioural epigenetics and improve understanding of the fundamental mechanisms that shape individual vulnerability and resilience to adverse behavioural outcomes.
  • 6.   Monday 09:00 - 10:40 Room: Room F Chair Laurence Lanfumey, France Presentations 09:00-09:25 S.11.01: Epigenetics in ageing and Alzheimer's disease Daniel L. A. Van Den Hove, The Netherlands 09:25-09:50 S.11.02: Epigenetic control of stress-induced gene transcription and behaviour: relevance to PTSD Johannes M.H.M. Reul, United Kingdom 09:50-10:15 S.11.03: Epigenetic implications in schizophrenia, bipolar disorder and autism Hamid Abdolmaleky, USA 10:15-10:40 S.11.04: Heat shock factors and epigenetics in the fetal alcohol syndrome Valerie Mezger, France Session Type Symposium Track Interface Research track              
  • 7.     S.12: New targets for treating depression and anxiety: preclinical and clinical studies Monday 09:00 - 10:40 Room: Room J Chair Nicoletta Brunello, Italy Presentations 09:00-09:12 S.12.01: Identification of a significant role for the ventral hippocampus in neuropeptide S-elicited anxiolysis Irina Ionescu, Germany 09:12-09:24 S.12.02: Histaminergic regulation of presumed serotonin neurons in the dorsal raphe nucleus Kara Panetta, United Kingdom 09:25-09:37 S.12.03: Effect of early life experiences on brain structure and function: neurogenesis and decision making Manila Loi, The Netherlands 09:37-09:49 S.12.04: Targeting postsynaptic density protein 95(PSD-95)/Discs large/Zonula occludens-1 (PDZ)-interactions of the glutamatergic synapse in animal models of depression Florian Freudenberg, Germany 09:50-10:02 S.12.05: Serotonin regulates hippocampal synaptic plasticity and object memory in mice Sebastian Fernandez, France 10:02-10:14 S.12.06: Corticotropin releasing hormone and serotonin - the neuropsychopharmacology of fear learning deficit from rodents to humans
  • 8.   Ivo Heitland, The Netherlands 10:15-10:27 S.12.07: Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response Gaël Quesseveur, France 10:27-10:39 S.12.08: Lithium-regulated genes in peripheral cell models of bipolar- affective patients Sarah Kittel-Schneider, Germany Session Type Junior Scientists symposium Track Preclinical Research track                              
  • 9.   S.15: Immunogenetics and psychiatric disorders This symposium deals with the question whether immune mediated tissue injury of the brain in early life may increase the susceptibility for developing schizophrenia or bipolar disorders. It will review evidence for a genetic association between genes coding for immune related molecules and the incidence of the respective psychiatric disorders. It will discuss the effect of childhood maltreatment on stress related immunological abnormalities and their possible relevance for brain development and function. Similarly the influence of early life infections of the central nervous system on the development of psychiatric disorders later in life will be reviewed. Finally, a new concept will be discussed, suggesting that infection or immune responses in the central nervous system induces the expression of antigens, encoded by endogenous retroviruses of the HERV-W family, which have been shown before to amplify pro-inflammatory and neurotoxic cascades. Such a mechanism may provide a pathogenetic link between genetic and environmental factors operating in increasing the susceptibility for schizophrenia and bipolar disease.
  • 10.   Monday 14:30 - 16:10 Room: Room F Chairs Eero Castrén, Finland Marion Leboyer, France Presentations 14:30-14:55 S.15.01: Immunogenetics: a molecular approach to the modulation of emotion and cognitive processes Bernhard T. Baune, Australia 14:55-15:20 S.15.02: Childhood maltreatment and the course of depression: the role of inflammation Andrea Danese, United Kingdom 15:20-15:45 S.15.03: Immunogenetic background in schizophrenia and bipolar disorder Ryad Tamouza, France 15:45-16:10 S.15.04: Role of Human Endogenous Retroviruses (HERVs) in psychotic disorder Hervé Perron, Switzerland Session Type Symposium Track Interface Research track            
  • 11.       S.25: Genetic implications in bipolar disorder Studies focused on genetic factors involved in both the response to drugs prescribed in bipolar patients and their side effects, would not only increase the quality of prescriptions, but also would contribute to a better understanding of the aetiology and the heterogeneity of bipolar disorder. Results from genetic studies could also bring us new biological tools that may optimize the detection of high-risk populations, such as suicidal patients. The aim of this symposium is to provide an update on most recent results from genetic studies, including pharmacogenetics. The topics of this symposium will be focused on recent results from pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment. In the second presentation, molecular data that differentiates lithium responders from non-responders will be discussed. Results from an on-going exon sequencing study, investigating the genetics of lithium responsive families, will also be exposed. Regarding pharmacogenetics of side effects in bipolar disorder, data from studies focused on the genetic variants that could influence the emergence of antipsychotic induced extrapyramidal symptoms, will be analysed. Lastly, recent results concerning the possible association between genetic variability at pathways involved in the mechanism of action of lithium and the emergence of suicidal behaviour in bipolar disorder will be presented.
  • 12.   Wednesday 09:00 - 10:40 Room: Auditorium Chair István Bitter, Hungary Presentations 09:00-09:25 S.25.01: Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment Leif Bertilsson, Sweden 09:25-09:50 S.25.02: Molecular genetic aspects to serotonergic drugs in bipolar disorder Xenia Gonda, Hungary 09:50-10:15 S.25.03: Pharmacogenetics of efficacy and treatment side effects in bipolar disorder Alessandro Serretti, Italy 10:15-10:40 S.25.04: Genetics of suicidal behaviour in bipolar disorder: an update Antoni Benabarre, Spain Session Type Symposium Track Clinical Treatment track  

×